This week from Drug Target Review...
EDITOR'S PICK
Swedish researchers unveiled a new cancer protein profile database compiled from artificial intelligence and machine learning.
Cancer prediction medicine gained a boost with the recent unveiling of a new cancer protein profile database compiled from artificial intelligence (AI) and machine learning. The new open-access Disease Blood Atlas provides a first-ever map of the proteome signature in blood from cancer patients. Read more>>>
===
TRENDING THIS WEEK
US researchers find that SARS-CoV-2 bivalent antibodies can continue to neutralise Omicron and Omicron lineages. Read more>>>
US researchers found high levels of XBP1s in lung cancer cells, which plays a key part in regulating the local immune environment in lung tumours, and can be disabled to increase anti-cancer immunity. Read more>>>
Drug Target Review’s Izzy Wood spoke to Joseph Hernandez, CEO of Blue Water Vaccines, about developing transformational vaccines to address significant health challenges globally. Read more>>>
===
WHAT TO LISTEN TO
Tune into this podcast to hear experts discuss imaging and obtaining data from organoids!
In this episode, sponsored by Molecular Devices, we cover the advantages of three-dimensional imaging over two-dimensional and how to obtain quality data from organoids.
===
WHAT TO WATCH
Ranging from decoding cancer inflammation to engineering cell lines and everything in between - discover our range of upcoming live webinars and on-demand sessions which are completely FREE to join.
===
JOIN THE COMMUNITY
Get your FREE subscription to Drug Target Review to stay up to date with the most pressing topics and trends in drug discovery and early-phase therapeutic development.
Cut down on screen time by listening to our podcasts, get intimate during our webinars or sip a cup of coffee whilst flicking through our journal. As a member, you’ll also gain exclusive access to:
We provide compelling content contributed by the world's most respected scientists, key opinion leaders and influencers.